Effects of Physical Exercise on Postmenopausal Risk Factors in Women With Osteopenia (ACTLIFE)

Effects of an Optimized 13-month Physical Exercise on (Early)-Postmenopausal Risk Factors in Women With Osteopenia and Osteoporosis (Actlife)

Menopause usually have a serious impact on a woman's life, associated with negative consequences for health and quality of life. Early preventive assessments are very difficult to implement due to the complex hormone-deficiency-induced effects on a large variety of organs and systems with estrogen receptors. In fact, only a few types of interventions have the potential to comprehensively improve the various risk factors and complaints of the menopausal transition. In detail, however, not every form of exercise training or every training protocol is effective for exerting positive effects on selected risk factors. In particular, the training concept for addressing musculoskeletal or cardio-metabolic risk factors differ fundamentally.

In several studies, we confirmed the effect of different complex training programs on risk factors of different postmenopausal female cohorts with special consideration of osteoporotic aspects. The training programs applied in this context were characterized by the consistent implementation of recognized training principles and an in general exercise intensity-oriented approach. Recent studies confirmed the effectiveness of this proceeding for women with relevant postmenopausal risk factors including low bone strength. However, the crucial issue of the most effective, feasible and easily customizable training protocol for addressing postmenopausal risk factors remains to be answered, taking into account that the majority of exercise programs were realized in an ambulatory group setting.

The aim of the study will be to evaluate the effects of an optimized physical training on risk factors and complaints of (early) postmenopausal women with special consideration of the osseous fracture risk.

Note (05.06.2020): Of importance, the intervention has to be cancelled due to COVID-19 lockdown in March 2020 after 13 months of intervention.

Study Overview

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Bavaria
      • Erlangen, Bavaria, Germany, 91052
        • Institute of Medical Physics, Friedrich Alexander University Erlangen-Nürnberg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

48 years to 58 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • (early)postmenopausal women, ( normal menopause, 1-5 years post)
  • Osteopenia and osteoporosis at the lumbar spine or femoral neck Bone Mineral Density (BMD) <-1.0 standard deviation (SD) T-Score, WHO)

Exclusion Criteria:

  • BMD <-4.0 SD T-Score (BMD threshold for pharmaceutical therapy according to Dachverband Osteologie (DVO) guideline (mandatory for Germany, Austria, Suisse) for woman 50-60 years).
  • Prevalent clinical, low-trauma fractures
  • Diseases and drugs with relevant effects on bone and muscle metabolism (e.g. glucocorticoids >7.5 mg/d or bisphosphonate therapy); individual case assessment
  • Diseases and drugs with relevant effects on cardiometabolic risk factors (e.g. severe hypertension with corresponding medical therapy); individual case assessment
  • Severe cardiovascular events (e.g. stroke, coronary infarction) in the past.
  • Other conditions, diseases that exclude exercise training in a group (≤10 persons).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: exercise
Exercise group
Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
SHAM_COMPARATOR: control
active control group
control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
BMD Lumbar Spine
Time Frame: from baseline to 13 month follow-up
Bone Mineral Density (BMD) at the lumbar spine region of interest as determined by Dual Energy x-Ray Absorptiometry (DXA)
from baseline to 13 month follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
BMD total Hip
Time Frame: from baseline to 13 month follow-up
Bone Mineral Density at the total hip region of interest as determined by DXA
from baseline to 13 month follow-up
Para-vertebral muscle density
Time Frame: from baseline to 13 month follow-up
Muscle density at the para-vertebral region as determined by Magnetic Resonance Imaging (MRI)
from baseline to 13 month follow-up
Mid-thigh muscle density
Time Frame: from baseline to 13 month follow-up
Muscle density at the mid-thigh region as determined by MRI
from baseline to 13 month follow-up
Metabolic Syndrome
Time Frame: from baseline to 13 month follow-up
Metabolic Syndrome Z-Score according to the Internationale Diabetes Federation (IDF)
from baseline to 13 month follow-up
Visceral body fat
Time Frame: from baseline to 13 month follow-up
Visceral body fat as determined by Magnetic Resonance Imaging (MRI)
from baseline to 13 month follow-up
Total body fat
Time Frame: from baseline to 13 month follow-up
Total body fat as determined by whole body DXA
from baseline to 13 month follow-up
Total Lean Body Mass
Time Frame: from baseline to 13 month follow-up
Total Lean Body Mass as determined by whole body DXA
from baseline to 13 month follow-up
Menopausal complaints
Time Frame: from baseline to 13 month follow-up
Menopausal complaints as determined by the Menopause Rating Scale (German version. Questionnaire with 11 items; scale from 0 (no complaints/problems) to 4 (very severe complaints/problem)
from baseline to 13 month follow-up
Maximum leg strength
Time Frame: from baseline to 13 month follow-up
Maximum isokinetic leg extensor strength as determined by an isokinetic leg press
from baseline to 13 month follow-up
Total fat rate
Time Frame: from baseline to 13 month follow-up
Total fat rate as determined by Bio Impedance technique (BIA)
from baseline to 13 month follow-up
Fat free mass
Time Frame: from baseline to 13 month follow-up
Fat free mass as determined by BIA
from baseline to 13 month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michael Hettchen, MSc, Institute of Medical Physics, University of Erlangen-Nurnberg, Germany

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 15, 2019

Primary Completion (ACTUAL)

March 13, 2020

Study Completion (ACTUAL)

June 5, 2020

Study Registration Dates

First Submitted

May 20, 2019

First Submitted That Met QC Criteria

May 21, 2019

First Posted (ACTUAL)

May 22, 2019

Study Record Updates

Last Update Posted (ACTUAL)

June 9, 2020

Last Update Submitted That Met QC Criteria

June 5, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • ER_ACTLIFE

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteopenia, Osteoporosis

Clinical Trials on High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)

3
Subscribe